You searched for: nosocomial (Engelska - Maltesiska)

nosocomial infection
infezzjoni nożokomjali

nosocomial pneumonia including ventilator– associated pneumonia
infezzjoni pulmonite li tittieħed minn ġo sptar, inkluż pulmonite assoċjata ma ’ apparat li jagħti r - respirazzjoni artifiċjali

strengthening capacities with regard to blood transfusion and nosocomial safety;
(ċ) tisħiħ tal-kapaċitajiet fir-rigward tat-trasfużjoni tad-demm u s-sigurtà nosokomjali;

each infusion lasts for one hour, although some patients with nosocomial pneumonia may need infusions lasting four hours.
kull infużjoni ddum siegħa, għalkemm xi pazjenti bi pnewmonja nożokomjali jista’ jenħtieġu infużjonijiet li jdumu erba’ sigħat.

promote measures to improve patient safety through high quality and safe healthcare, including in relation to nosocomial infections.
il-promozzjoni ta’ miżuri biex tittejjeb is-sigurtà tal-pazjenti permezz ta’ kura tas-saħħa ta’ kwalità għolja u sigurta li tinkludi dak li għandu x’jaqsam ma' infezzjoniiet li jittieħdu mill-isptar;

the rate of resistance to methicillin is around 20 to 50% among all staphylococcal species and is usually higher in nosocomial isolates.
ir- rata ta ’ reżistenza għal methicillin hija madwar 20 sa 50% fost l - ispeċi ta ’ staphylococci kollha u ġeneralment hija ogħla f’ iżolati minn infezzjonijiet li jittieħdu minn sptar.

the european medicines agency has deferred the obligation to submit the results of studies with telavancin in one or more subsets of the paediatric population in nosocomial pneumonia.
l-aġenzija ewropea dwar il-mediċini ddeferit l-obbligu li jiġu sottomessi riżultati ta’ studju b’telavancin f’sottosett wieħed jew aktar tal-popolazzjoni pedjatrika bi pnewmonja nosokomijali.

however, the committee considered that vibativ could be valuable for treating patients with nosocomial pneumonia known or believed to be caused by mrsa for whom other treatments are not suitable.
madankollu, il-kumitat qies li vibativ jista’ jkun utli fil-kura ta’ pazjenti bil-pnewmonja nosokomijali li hija magħrufa jew maħsuba li tiġi kkawżata minn mrsa u li kuri oħra ma jkunux adegwati għalihom.

the chmp concluded that, although vibativ had been shown to be effective in treating both nosocomial pneumonia and complicated infections of the skin and soft tissue, its toxic effect on the kidneys was an important safety concern.
is-chmp ikkonkluda li, minkejja li ntwera li vibativ kien effettiv fil-kura kemm tal-pnewmonja nosokomijali kif ukoll tal-infezzjonijiet ikkumplikati tal-ġilda u tat-tessut artab, l-effett tossiku tiegħu fuq il-kliewi kien ta’ tħassib importanti fir-rigward tas-sigurtà.

there may be a particular risk of selecting for ciprofloxacin-resistant bacteria during extended durations of treatment and when treating nosocomial infections and/ or infections caused by staphylococcus and pseudomonas species.
29 selezzjoni għall- batterja reżistenti għal ciprofloxacin waqt kura fit- tul u meta jiġu kkurati infezzjonijiet li jittieħdu minn sptar u/ jew infezzjonijiet ikkawżati mill- ispeċi staphylococcus u pseudomonas.

therefore, the chmp decided that vibativ’s benefits are only greater than its risks for patients who are severely ill with nosocomial pneumonia and are under close observation in hospital, and recommended that it be given marketing authorisation.
għaldaqstant, is-chmp iddeċieda li l-benefiċċji ta’ vibativ huma biss akbar mir-riskji tiegħu għal pazjenti li jkunu serjament morda bil- pnewmonja nosokomijali u li jkunu taħt osservazzjoni mill-qrib fi isptar, u rrakkomanda li jingħata awtorizzazzjoni għat-tqegħid fis-suq.

two studies compared doribax with piperacillin/tazobactam or imipenem in a total of 979 patients with nosocomial pneumonia; two studies compared doribax with meropenem in a total of 962 patients with complicated infections in the abdomen;
żewġ studji qabblu doribax ma’ piperacillin/tazobactam jew ma’ imipenem f’total ta’ 979 pazjent bi pnewmonja nażokomjali;

doribax has been studied in five main studies that compared doribax with other antibiotics: • two studies compared doribax with piperacillin/ tazobactam or imipenem in a total of 979 patients with nosocomial pneumonia; • two studies compared doribax with meropenem in a total of 962 patients with complicated infections in the abdomen; • one study compared doribax with levofloxacin in 753 patients with complicated urinary tract infections.
doribax ġie studjat f’ ħames studji ewlenin li qabblu doribax ma ’ antibijotiċi oħrajn: • żewġ studji qabblu doribax ma ’ piperacillin/ tazobactam jew ma ’ imipenem f’ total ta ’ 979 pazjent bi pnewmonja nażokomjali; • żewġ studji qabblu doribax ma ’ meropenem f’ total ta ’ 962 pazjent b’ infezzjonijiet ikkumplikati fl- addome; • studju wieħed qabbel doribax ma ’ levofloxacin f’ 753 pazjent b’ infezzjonijiet ikkumplikati tal - passaġġi awrinarji.